
I-Mab Investor Relations Material
Latest events

H1 2024
I-Mab
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from I-Mab
Access all reports
I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of innovative biologics, particularly in the fields of immuno-oncology and immuno-inflammation. The company has a diverse pipeline, including several antibody-based therapies aimed at treating various forms of cancer. These include drugs in different phases of clinical trials, such as Uliledlimab for solid tumors and Lemzoparlimab for hematologic malignancies. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.
Key slides for I-Mab


Q3 2024
I-Mab


Corporate Presentation
I-Mab
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
IMAB
Country
🇺🇸 United States